According to people with knowledge of the matter, Mumbai-based drugmaker USV is in advanced discussions to acquire the trademark for Novartis' diabetes drug Jalra in a deal valued at more than Rs. 200 crore, reported The Economic Times.
Sources indicated that the family-run USV is likely to announce the acquisition soon.
Jalra, which contains the DPP-4 inhibitor vildagliptin, is used to treat adults with type 2 diabetes, either alone or in combination with other medicines.
With Novartis' patent for vildagliptin set to expire this month in India, it is expected to see the entry of branded generic versions entering the Indian market, the news source said.
The news source added that USV has a strong foothold in the Indian oral anti-diabetes products segment with brands such as Glycomet, Glycomet GP and Pirox.
To read more NewsPoints articles, click here.